Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients

被引：37
|
作者：
Park, Jin-Mo [1 ]
Kim, Sun-Young [2 ]
Park, Donghwi [3 ]
Park, Jin-Sung [4 ]
机构：
[1] Dongguk Univ, Coll Med, Dept Neurol, Gyeongju Hosp, Gyeongju, South Korea
[2] Univ Ulsan, Ulsan Univ Hosp, Dept Neurol, Coll Med, Ulsan, South Korea
[3] Daegu Fatima Hosp, Dept Rehabil, Daegu, South Korea
[4] Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, 807 Hoguk Ro, Daegu 41944, South Korea
来源：
NEUROLOGICAL SCIENCES | 2020年 / 41卷 / 01期
基金：
新加坡国家研究基金会;
关键词：
Amyotrophic lateral sclerosis (ALS); Edaravone; Korean ALS; ALSFS-R; DOUBLE-BLIND; DECLINE; DISEASE;
D O I：
10.1007/s10072-019-04055-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS outside of Japan are not yet reported. This study aims to investigate effects of edaravone on ALS patients in the Korean population. The study included 22 patients with ALS who were treated with edaravone. Of the 16 patients who finished six cycles of treatment, a mean decline of ALSFRS-R after the treatments was 5.75 +/- 6.07 points and the average change of FVC was - 8.7 +/- 17.0%. Patients experienced only minor adverse events. This study reports on the open-label study of edaravone on patients in Korea for ALS patients, which showed a modest effect of edaravone in this population of ALS patients.
引用
收藏
页码：119 / 123
页数：5
相关论文
共 50 条
  • [1] Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
    Jin-Mo Park
    Sun-Young Kim
    Donghwi Park
    Jin-Sung Park
    Neurological Sciences, 2020, 41 : 119 - 123
  • [2] The Effect of Edaravone on Respiratory Function in Amyotrophic Lateral Sclerosis (ALS)
    McGrath, C.
    File, B.
    Guarnieri, J.
    Houseman, G.
    Oakley, L.
    Pasinelli, P.
    Ackrivo, J.
    West, F. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Amyotrophic Lateral Sclerosis (ALS) patients experience with Edaravone in Argentina
    Quarracino, Cecilia
    Bendersky, Mariana
    Morera, Natalia Bohorquez
    Rey, Roberto
    Rodriguez, Gabriel
    NEUROLOGY, 2020, 94 (15)
  • [4] The effect of edaravone on nerve excitability in patients with amyotrophic lateral sclerosis
    Isose, S.
    Shibuya, K.
    Ito, K.
    Koide, M.
    Araki, N.
    Honda, K.
    Misawa, S.
    Arai, K.
    Kuwabara, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 493 - 493
  • [5] Therapy options in amyotrophic lateral sclerosis (ALS)
    Dorst, J.
    Kuehnlein, P.
    Sperfeld, A. D.
    Ludolph, A. C.
    NERVENHEILKUNDE, 2007, 26 (05) : 362 - +
  • [6] Retrospective review of respiratory function in the Amyotrophic Lateral Sclerosis(ALS) veteran population with and without Edaravone therapy
    Thakore-James, Manisha
    Salajegheh, Mohammad
    James, Nikita
    NEUROLOGY, 2019, 92 (15)
  • [7] Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
    Neupane, Purushottam
    Thada, Pawan Kumar
    Singh, Pramod
    Faisal, Abdul Rafae
    Rai, Niraj
    Poudel, Prabhat
    Waleed, Madeeha Subhan
    Quinonez, Jonathan
    Ruxmohan, Samir
    Jain, Esha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [8] Edaravone for the treatment of amyotrophic lateral sclerosis
    Yoshino, Hiide
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (03) : 185 - 193
  • [9] Edaravone in the treatment of amyotrophic lateral sclerosis
    Kuzma-Kozakiewicz, Magdalena
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2018, 52 (02) : 124 - 128
  • [10] Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration
    Nagase, Midori
    Yamamoto, Yorihiro
    Miyazaki, Yusuke
    Yoshino, Hiide
    REDOX REPORT, 2016, 21 (03) : 104 - 112
12345